热门资讯> 正文
89 bio提供2025年业务更新和展望
2025-01-13 21:36
- 89bio (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, on Monday provided a corporate update and business outlook for 2025.
- The company completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG) and said the topline 26-week data is expected in the second half of 2025.
- The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials.
- Cash, cash equivalents, and marketable securities totaled approximately $440 million as of December 31, 2024.
- “We continue to advance our Phase 3 programs toward potential Biologics License Application (BLA) and Marketing Authorization Application (MAA) filings, aiming to transform care for patients living with MASH and SHTG,” said Rohan Palekar, CEO of 89bio.
- 89bio (NASDAQ:ETNB) shares were up 2.46% in pre-market trading on Monday.
More on 89bio
- 89bio: Surviving A Competitive Space - For Now
- 89bio drops 2%, prices $125M stock offering
- 89bio announces proposed underwritten public offering of common stock and pre-funded warrants
- Seeking Alpha’s Quant Rating on 89bio
- Historical earnings data for 89bio
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
